RxDoctor Payments Data

Khalid Chaudry, MD

Internal Medicine · Corbin, KYNPI 1306895966

Payments from drug & device makers

$2,505in general payments, 2019–2025

Across 151 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$530
  • Merck$519
  • Pfizer$405
  • Novartis$296
  • Amgen$102
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$92
  • plus $561 from 10 others

What the payments were for

  • Food & beverage$2,37395%
  • Education$1325%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,505 in reported general payments places this provider in the 80th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$124,623
Medicare patients
768
Services billed
2,139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban321$300,295
EntrestoSacubitril/Valsartan224$199,920
Repatha SureclickEvolocumab132$128,103
LeqvioInclisiran Sodium19$60,956
JanuviaSitagliptin Phosphate28$44,140
JardianceEmpagliflozin26$38,818
Praluent PenAlirocumab33$38,735
FarxigaDapagliflozin Propanediol45$34,531
XareltoRivaroxaban18$26,152
NamzaricMemantine Hcl/Donepezil Hcl21$26,033
TradjentaLinagliptin25$23,238
OzempicSemaglutide22$20,045
MounjaroTirzepatide14$14,660
Valsartan224$7,543
Metoprolol Succinate432$4,663

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$405$300,295321 claims
NovartisEntresto, Leqvio$296$260,876243 claims
Boehringer IngelheimJardiance, Tradjenta$60$62,05551 claims
MerckJanuvia$519$44,14028 claims
AstraZenecaFarxiga$530$34,53145 claims
Johnson & JohnsonXarelto$62$26,15218 claims
Novo NordiskOzempic$91$20,04522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Corbin

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →